| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.673 | 0.006 | 0.906 | Caspase 3 stimulant | 0.906 0.002 DBMET01630 | DBMET01630 | |
| 0.662 | 0.005 | 0.702 | Superoxide dismutase inhibitor | 0.702 0.004 DBMET01630 | DBMET01630 | |
| 0.649 | 0.039 | 0.87 | Apoptosis agonist | 0.87 0.009 DBMET01630 | DBMET01630 | |
| 0.612 | 0.017 | 0.612 | Aldehyde oxidase inhibitor | 0.288 0.07 DBMET01630 | ||
| 0.615 | 0.034 | 0.615 | Caspase 9 stimulant | 0.483 0.067 DBMET01630 | ||
| 0.587 | 0.011 | 0.587 | Apoptosis antagonist | 0.422 0.033 DBMET01630 | ||
| 0.591 | 0.017 | 0.591 | Vasodilator, peripheral | 0.262 0.118 DBMET01630 | ||
| 0.576 | 0.004 | 0.576 | Alpha-N-acetylglucosaminidase inhibitor | 0.552 0.004 DBMET01630 | ||
| 0.591 | 0.056 | 0.635 | Antiinflammatory | 0.635 0.044 DBMET01630 | DBMET01630 | |
| 0.54 | 0.039 | 0.607 | Transcription factor NF kappa B inhibitor | 0.607 0.03 DBMET01630 | DBMET01630 | |
| 0.503 | 0.012 | 0.503 | Angiogenesis stimulant | |||
| 0.505 | 0.015 | 0.568 | Hypoglycemic | 0.568 0.01 DBMET01630 | DBMET01630 | |
| 0.515 | 0.03 | 0.515 | Cholesterol antagonist | 0.305 0.088 DBMET01630 | ||
| 0.5 | 0.02 | 0.546 | Antioxidant | 0.546 0.015 DBMET01630 | DBMET01630 | |
| 0.481 | 0.005 | 0.481 | NOS3 expression enhancer | 0.234 0.03 DBMET01630 | ||
| 0.502 | 0.028 | 0.502 | Histamine release inhibitor | 0.356 0.097 DBMET01630 | ||
| 0.489 | 0.036 | 0.489 | Immunosuppressant | |||
| 0.468 | 0.018 | 0.608 | Nitric oxide antagonist | 0.608 0.009 DBMET01630 | DBMET01630 | |
| 0.478 | 0.032 | 0.478 | GABA C receptor rho-3 antagonist | 0.476 0.033 DBMET01630 | ||
| 0.443 | 0.004 | 0.443 | Succinate dehydrogenase inhibitor | 0.421 0.004 DBMET01630 | ||
| 0.428 | 0.017 | 0.428 | Peroxidase inhibitor | 0.192 0.061 DBMET01630 | ||
| 0.428 | 0.025 | 0.583 | Free radical scavenger | 0.583 0.009 DBMET01630 | DBMET01630 | |
| 0.453 | 0.05 | 0.453 | 5 Hydroxytryptamine release inhibitor | 0.303 0.161 DBMET01630 | ||
| 0.436 | 0.039 | 0.436 | 5 Hydroxytryptamine release stimulant | 0.298 0.071 DBMET01630 | ||
| 0.412 | 0.023 | 0.412 | Amyloid beta aggregation inhibitor | 0.218 0.069 DBMET01630 | ||
| 0.412 | 0.026 | 0.412 | DNA damaging | |||
| 0.414 | 0.034 | 0.414 | Lipoxygenase inhibitor | 0.23 0.114 DBMET01630 | ||
| 0.371 | 0.011 | 0.371 | Amylase inhibitor | 0.35 0.013 DBMET01630 | ||
| 0.381 | 0.025 | 0.381 | Sigma receptor agonist | 0.346 0.031 DBMET01630 | ||
| 0.364 | 0.015 | 0.463 | Melanin inhibitor | 0.463 0.008 DBMET01630 | DBMET01630 | |
| 0.352 | 0.004 | 0.352 | Histone deacetylase SIRT1 stimulant | |||
| 0.352 | 0.004 | 0.352 | Histone deacetylase stimulant | |||
| 0.36 | 0.013 | 0.36 | Phospholipase C inhibitor | 0.2 0.043 DBMET01630 | ||
| 0.414 | 0.071 | 0.415 | Antibacterial | 0.415 0.07 DBMET01630 | DBMET01630 | |
| 0.361 | 0.022 | 0.361 | Anesthetic general | 0.187 0.082 DBMET01630 | ||
| 0.379 | 0.043 | 0.379 | Vasodilator, coronary | 0.281 0.104 DBMET01630 | ||
| 0.35 | 0.016 | 0.35 | Tyrosine 3 hydroxylase inhibitor | 0.295 0.035 DBMET01630 | ||
| 0.41 | 0.085 | 0.41 | Cyclophilin D inhibitor | |||
| 0.36 | 0.036 | 0.36 | Platelet antagonist | 0.325 0.045 DBMET01630 | ||
| 0.363 | 0.042 | 0.363 | Calcium channel activator | 0.325 0.069 DBMET01630 | ||
| 0.374 | 0.056 | 0.374 | Antithrombotic | 0.312 0.081 DBMET01630 | ||
| 0.322 | 0.008 | 0.322 | GABA C receptor agonist | 0.251 0.013 DBMET01630 | ||
| 0.35 | 0.039 | 0.35 | Interleukin antagonist | |||
| 0.319 | 0.013 | 0.319 | Amyloid beta precursor protein antagonist | 0.274 0.024 DBMET01630 | ||
| 0.322 | 0.018 | 0.322 | Peptidyltransferase inhibitor | 0.175 0.137 DBMET01630 | ||
| 0.341 | 0.037 | 0.341 | Transcription factor STAT inhibitor | 0.294 0.059 DBMET01630 | ||
| 0.326 | 0.025 | 0.326 | Dual specificity phosphatase inhibitor | |||
| 0.333 | 0.034 | 0.333 | Interleukin agonist | 0.225 0.098 DBMET01630 | ||
| 0.333 | 0.04 | 0.333 | Hypolipemic | |||
| 0.331 | 0.04 | 0.331 | Transcription factor STAT3 inhibitor | 0.306 0.051 DBMET01630 | ||
| 0.393 | 0.107 | 0.437 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.437 0.07 DBMET01630 | DBMET01630 | |
| 0.311 | 0.027 | 0.311 | Hepatoprotectant | 0.152 0.108 DBMET01630 | ||
| 0.287 | 0.005 | 0.287 | Triose-phosphate isomerase inhibitor | 0.258 0.006 DBMET01630 | ||
| 0.28 | 0.004 | 0.28 | Phenylalanine 4-hydroxylase inhibitor | 0.104 0.024 DBMET01630 | ||
| 0.365 | 0.091 | 0.365 | 15-Lipoxygenase inhibitor | |||
| 0.277 | 0.004 | 0.277 | Keratolytic | 0.117 0.023 DBMET01630 | ||
| 0.293 | 0.02 | 0.293 | Protein-tyrosine phosphatase inhibitor | 0.175 0.059 DBMET01630 | ||
| 0.283 | 0.011 | 0.291 | UDP-glucose 4-epimerase inhibitor | 0.291 0.011 DBMET01630 | DBMET01630 | |
| 0.283 | 0.011 | 0.283 | Cystathionine beta-synthase inhibitor | 0.207 0.023 DBMET01630 | ||
| 0.335 | 0.063 | 0.335 | 12-Lipoxygenase inhibitor | 0.217 0.133 DBMET01630 | ||
| 0.328 | 0.06 | 0.328 | Spasmolytic | |||
| 0.272 | 0.005 | 0.272 | Alcohol oxidase inhibitor | 0.255 0.005 DBMET01630 | ||
| 0.278 | 0.013 | 0.278 | 5-Lipoxygenase inhibitor | 0.171 0.031 DBMET01630 | ||
| 0.274 | 0.01 | 0.274 | Ferrochelatase inhibitor | 0.242 0.014 DBMET01630 | ||
| 0.312 | 0.051 | 0.312 | Insulysin inhibitor | 0.288 0.066 DBMET01630 | ||
| 0.267 | 0.011 | 0.374 | Interleukin 1b antagonist | 0.374 0.005 DBMET01630 | DBMET01630 | |
| 0.267 | 0.015 | 0.309 | Aldehyde dehydrogenase inhibitor | 0.309 0.011 DBMET01630 | DBMET01630 | |
| 0.253 | 0.008 | 0.253 | Beta glucuronidase inhibitor | 0.148 0.026 DBMET01630 | ||
| 0.255 | 0.014 | 0.267 | 5 Hydroxytryptamine 3E antagonist | 0.267 0.01 DBMET01630 | DBMET01630 | |
| 0.249 | 0.009 | 0.249 | Catalase inhibitor | 0.232 0.01 DBMET01630 | ||
| 0.265 | 0.026 | 0.265 | Interferon gamma antagonist | 0.188 0.046 DBMET01630 | ||
| 0.272 | 0.035 | 0.272 | P-glycoprotein inhibitor | |||
| 0.308 | 0.076 | 0.308 | Immunostimulant | 0.236 0.102 DBMET01630 | ||
| 0.279 | 0.051 | 0.328 | DNA synthesis inhibitor | 0.328 0.035 DBMET01630 | DBMET01630 | |
| 0.282 | 0.055 | 0.282 | 5 Hydroxytryptamine uptake stimulant | 0.278 0.058 DBMET01630 | ||
| 0.232 | 0.01 | 0.232 | Carbonic anhydrase VI inhibitor | 0.112 0.033 DBMET01630 | ||
| 0.249 | 0.027 | 0.249 | Protein kinase stimulant | 0.145 0.072 DBMET01630 | ||
| 0.275 | 0.058 | 0.275 | Vasodilator | 0.23 0.083 DBMET01630 | ||
| 0.228 | 0.012 | 0.228 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.137 0.031 DBMET01630 | ||
| 0.235 | 0.02 | 0.235 | Protein-tyrosine phosphatase 1B inhibitor | |||
| 0.261 | 0.046 | 0.261 | Neuropeptide Y2 antagonist | 0.234 0.073 DBMET01630 | ||
| 0.248 | 0.036 | 0.248 | Insulin sensitizer | 0.177 0.099 DBMET01630 | ||
| 0.256 | 0.044 | 0.256 | DNA methyltransferase I inhibitor | 0.17 0.087 DBMET01630 | ||
| 0.223 | 0.013 | 0.223 | Carbonic anhydrase III inhibitor | 0.121 0.043 DBMET01630 | ||
| 0.23 | 0.021 | 0.23 | Cholesterol synthesis inhibitor | 0.204 0.026 DBMET01630 | ||
| 0.268 | 0.06 | 0.268 | Gastrin inhibitor | 0.198 0.152 DBMET01630 | ||
| 0.211 | 0.006 | 0.211 | Peroxisome proliferator-activated receptor gamma agonist | |||
| 0.22 | 0.017 | 0.22 | Arachidonic acid antagonist | 0.181 0.052 DBMET01630 | ||
| 0.226 | 0.024 | 0.267 | Interleukin 1 antagonist | 0.267 0.015 DBMET01630 | DBMET01630 | |
| 0.228 | 0.029 | 0.228 | Tubulin antagonist | |||
| 0.206 | 0.011 | 0.206 | Adenylate cyclase stimulant | 0.166 0.039 DBMET01630 | ||
| 0.203 | 0.01 | 0.203 | Creatine kinase inhibitor | 0.112 0.047 DBMET01630 | ||
| 0.205 | 0.013 | 0.205 | Calcium antagonist | 0.107 0.043 DBMET01630 | ||
| 0.206 | 0.018 | 0.206 | Carbonic anhydrase XV inhibitor | 0.119 0.047 DBMET01630 | ||
| 0.212 | 0.023 | 0.212 | Alkylator | 0.145 0.049 DBMET01630 | ||
| 0.248 | 0.06 | 0.248 | Antimitotic | |||
| 0.199 | 0.012 | 0.199 | HIV-1 integrase (Overall Integration) inhibitor | 0.115 0.043 DBMET01630 | ||
| 0.195 | 0.012 | 0.195 | Phosphofructokinase-1 inhibitor | 0.178 0.014 DBMET01630 | ||
| 0.188 | 0.005 | 0.188 | Ca2+-transporting ATPase inhibitor | 0.166 0.016 DBMET01630 | ||
| 0.199 | 0.015 | 0.236 | Adenylate kinase inhibitor | 0.236 0.011 DBMET01630 | DBMET01630 | |
| 0.238 | 0.055 | 0.238 | DNA methylase inhibitor | 0.163 0.107 DBMET01630 | ||
| 0.192 | 0.01 | 0.192 | HIV-1 integrase (3'-Processing) inhibitor | 0.185 0.011 DBMET01630 | ||
| 0.211 | 0.03 | 0.211 | Monophenol monooxygenase inhibitor | 0.135 0.053 DBMET01630 | ||
| 0.195 | 0.014 | 0.195 | Sphingosine 1-phosphate receptor 5 antagonist | |||
| 0.188 | 0.009 | 0.188 | Heat shock protein 70 antagonist | 0.162 0.025 DBMET01630 | ||
| 0.204 | 0.026 | 0.204 | GABA C receptor rho-2 antagonist | 0.181 0.042 DBMET01630 | ||
| 0.228 | 0.051 | 0.228 | Nitric-oxide synthase stimulant | 0.199 0.091 DBMET01630 | ||
| 0.2 | 0.023 | 0.2 | Toll-Like receptor 2 antagonist | 0.147 0.054 DBMET01630 | ||
| 0.199 | 0.023 | 0.272 | Cathepsin H inhibitor | 0.272 0.012 DBMET01630 | DBMET01630 | |
| 0.225 | 0.055 | 0.225 | Neurotrophic factor enhancer | 0.164 0.118 DBMET01630 | ||
| 0.182 | 0.012 | 0.182 | NADH dehydrogenase inhibitor | 0.112 0.034 DBMET01630 | ||
| 0.2 | 0.031 | 0.23 | Mannose-6-phosphate isomerase inhibitor | 0.23 0.017 DBMET01630 | DBMET01630 | |
| 0.185 | 0.016 | 0.185 | Carbonic anhydrase XIII inhibitor | 0.18 0.017 DBMET01630 | ||
| 0.181 | 0.014 | 0.181 | Sphingosine 1-phosphate receptor 4 antagonist | 0.136 0.048 DBMET01630 | ||
| 0.313 | 0.146 | 0.313 | Calcium channel L-type activator | |||
| 0.229 | 0.065 | 0.229 | RNA-directed DNA polymerase inhibitor | 0.193 0.11 DBMET01630 | ||
| 0.18 | 0.015 | 0.18 | Porphobilinogen synthase inhibitor | 0.161 0.018 DBMET01630 | ||
| 0.173 | 0.008 | 0.173 | Glutathione S-transferase inhibitor | 0.099 0.038 DBMET01630 | ||
| 0.204 | 0.039 | 0.204 | MAO inhibitor | 0.106 0.085 DBMET01630 | ||
| 0.235 | 0.071 | 0.235 | Cyclic AMP phosphodiesterase inhibitor | |||
| 0.182 | 0.018 | 0.182 | Vanilloid 1 agonist | 0.142 0.047 DBMET01630 | ||
| 0.203 | 0.041 | 0.203 | Phospholipase A2 inhibitor | 0.145 0.08 DBMET01630 | ||
| 0.168 | 0.007 | 0.173 | Thioredoxin reductase inhibitor | 0.173 0.006 DBMET01630 | DBMET01630 | |
| 0.165 | 0.005 | 0.165 | Transcription factor AP-1 inhibitor | 0.056 0.052 DBMET01630 | ||
| 0.168 | 0.008 | 0.168 | Biliverdin reductase inhibitor | 0.108 0.016 DBMET01630 | ||
| 0.262 | 0.105 | 0.262 | Interleukin 2 agonist | |||
| 0.16 | 0.003 | 0.16 | Factor III inhibitor | 0.065 0.013 DBMET01630 | ||
| 0.172 | 0.016 | 0.172 | Folate antagonist | |||
| 0.175 | 0.019 | 0.175 | GABA C receptor antagonist | 0.132 0.042 DBMET01630 | ||
| 0.234 | 0.079 | 0.234 | Antiamyloidogenic | |||
| 0.168 | 0.014 | 0.168 | NAD(P)H dehydrogenase (quinone) inhibitor | 0.131 0.025 DBMET01630 | ||
| 0.194 | 0.042 | 0.294 | ATPase inhibitor | 0.294 0.007 DBMET01630 | DBMET01630 | |
| 0.165 | 0.014 | 0.165 | Toll-Like receptor 4 antagonist | 0.12 0.043 DBMET01630 | ||
| 0.169 | 0.022 | 0.169 | Sphingosine 1-phosphate receptor 2 antagonist | |||
| 0.176 | 0.03 | 0.176 | MAO B inhibitor | 0.087 0.069 DBMET01630 | ||
| 0.153 | 0.007 | 0.153 | GABA aminotransferase inhibitor | 0.127 0.014 DBMET01630 | ||
| 0.156 | 0.012 | 0.167 | Glutamate decarboxylase inhibitor | 0.167 0.01 DBMET01630 | DBMET01630 | |
| 0.154 | 0.01 | 0.177 | Ornithine decarboxylase inhibitor | 0.177 0.006 DBMET01630 | DBMET01630 | |
| 0.172 | 0.028 | 0.172 | Microtubule formation inhibitor | 0.165 0.03 DBMET01630 | ||
| 0.209 | 0.065 | 0.209 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.151 0.148 DBMET01630 | ||
| 0.147 | 0.004 | 0.147 | Aconitate hydratase inhibitor | 0.097 0.009 DBMET01630 | ||
| 0.156 | 0.014 | 0.156 | MAP kinase kinase 1 inhibitor | |||
| 0.154 | 0.012 | 0.154 | HIV-1 integrase (Strand Transfer) inhibitor | 0.131 0.015 DBMET01630 | ||
| 0.162 | 0.024 | 0.535 | TRPA1 agonist | 0.535 0.003 DBMET01630 | DBMET01630 | |
| 0.156 | 0.019 | 0.156 | GABA C receptor rho-1 antagonist | 0.125 0.036 DBMET01630 | ||
| 0.146 | 0.01 | 0.146 | Leukotriene synthesis inhibitor | |||
| 0.143 | 0.009 | 0.143 | Carbonic anhydrase VB inhibitor | 0.07 0.028 DBMET01630 | ||
| 0.145 | 0.012 | 0.145 | Carbamoyl phosphate synthetase inhibitor | 0.071 0.034 DBMET01630 | ||
| 0.23 | 0.097 | 0.264 | 5 Hydroxytryptamine 1E antagonist | 0.264 0.059 DBMET01630 | DBMET01630 | |
| 0.186 | 0.054 | 0.186 | Cytidine deaminase inhibitor | 0.127 0.094 DBMET01630 | ||
| 0.142 | 0.01 | 0.142 | Sphingosine 1-phosphate receptor 4 agonist | 0.066 0.048 DBMET01630 | ||
| 0.147 | 0.015 | 0.147 | Carbonic anhydrase V inhibitor | 0.076 0.038 DBMET01630 | ||
| 0.154 | 0.023 | 0.154 | Sphingomyelinase inhibitor | 0.086 0.078 DBMET01630 | ||
| 0.142 | 0.012 | 0.142 | Phosphodiesterase 6D inhibitor | 0.09 0.076 DBMET01630 | ||
| 0.159 | 0.032 | 0.159 | Expectorant | 0.089 0.083 DBMET01630 | ||
| 0.15 | 0.023 | 0.15 | Estrogen antagonist | |||
| 0.146 | 0.02 | 0.146 | Interleukin 2 antagonist | |||
| 0.159 | 0.034 | 0.159 | Aminopeptidase B inhibitor | 0.15 0.038 DBMET01630 | ||
| 0.148 | 0.023 | 0.156 | Prolactin inhibitor | 0.156 0.02 DBMET01630 | DBMET01630 | |
| 0.137 | 0.012 | 0.137 | Leukotriene antagonist | |||
| 0.154 | 0.03 | 0.154 | Mucolytic | 0.095 0.086 DBMET01630 | ||
| 0.127 | 0.004 | 0.127 | Squalene epoxidase inhibitor | 0.068 0.015 DBMET01630 | ||
| 0.161 | 0.038 | 0.161 | Adenylate cyclase inhibitor | |||
| 0.17 | 0.047 | 0.17 | Cell wall synthesis inhibitor | |||
| 0.147 | 0.026 | 0.147 | Transcription factor STAT6 inhibitor | 0.125 0.051 DBMET01630 | ||
| 0.132 | 0.011 | 0.132 | Acyl-CoA dehydrogenase inhibitor | 0.077 0.023 DBMET01630 | ||
| 0.144 | 0.025 | 0.144 | DOPA decarboxylase inhibitor | 0.122 0.043 DBMET01630 | ||
| 0.153 | 0.033 | 0.153 | Xanthine oxidase inhibitor | 0.11 0.053 DBMET01630 | ||
| 0.174 | 0.055 | 0.177 | Hexokinase inhibitor | 0.177 0.052 DBMET01630 | DBMET01630 | |
| 0.133 | 0.015 | 0.133 | Carbonic anhydrase VA inhibitor | 0.082 0.035 DBMET01630 | ||
| 0.128 | 0.01 | 0.128 | Mannitol-1-phosphate 5-dehydrogenase inhibitor | 0.114 0.012 DBMET01630 | ||
| 0.136 | 0.018 | 0.136 | Lanosterol 14 alpha demethylase inhibitor | 0.111 0.041 DBMET01630 | ||
| 0.129 | 0.011 | 0.129 | NMDA receptor agonist | 0.072 0.034 DBMET01630 | ||
| 0.174 | 0.057 | 0.174 | Neurotensin receptor agonist | 0.151 0.098 DBMET01630 | ||
| 0.158 | 0.042 | 0.158 | Cyclooxygenase 3 inhibitor | |||
| 0.124 | 0.008 | 0.124 | NMDA receptor glycine site agonist | 0.083 0.026 DBMET01630 | ||
| 0.133 | 0.019 | 0.133 | Glutamate dehydrogenase inhibitor | 0.104 0.029 DBMET01630 | ||
| 0.147 | 0.033 | 0.147 | Photosensitizer | 0.12 0.058 DBMET01630 | ||
| 0.141 | 0.027 | 0.141 | Breast cancer-resistant protein inhibitor | 0.126 0.035 DBMET01630 | ||
| 0.138 | 0.026 | 0.138 | Acetylcholine release stimulant | 0.123 0.043 DBMET01630 | ||
| 0.127 | 0.017 | 0.127 | Aminopeptidase I inhibitor | 0.079 0.043 DBMET01630 | ||
| 0.138 | 0.028 | 0.138 | Uric acid excretion stimulant | 0.094 0.059 DBMET01630 | ||
| 0.121 | 0.012 | 0.121 | Glycine receptor agonist | 0.079 0.039 DBMET01630 | ||
| 0.187 | 0.078 | 0.752 | Platelet adhesion inhibitor | 0.752 0.003 DBMET01630 | DBMET01630 | |
| 0.126 | 0.018 | 0.126 | CDC25A inhibitor | |||
| 0.121 | 0.014 | 0.121 | Prostaglandin EP2 antagonist | 0.057 0.044 DBMET01630 | ||
| 0.118 | 0.011 | 0.118 | Estrogen-related receptor beta agonist | 0.086 0.051 DBMET01630 | ||
| 0.111 | 0.004 | 0.111 | Glucose-6-phosphate isomerase inhibitor | 0.1 0.005 DBMET01630 | ||
| 0.192 | 0.086 | 0.261 | Pyruvate kinase inhibitor | 0.261 0.058 DBMET01630 | DBMET01630 | |
| 0.121 | 0.015 | 0.121 | HIV-1 integrase inhibitor | 0.12 0.015 DBMET01630 | ||
| 0.112 | 0.008 | 0.112 | Leukotriene B4 antagonist | |||
| 0.124 | 0.021 | 0.125 | Interleukin 5 antagonist | 0.125 0.021 DBMET01630 | DBMET01630 | |
| 0.151 | 0.05 | 0.151 | Pregnane X receptor agonist | 0.141 0.071 DBMET01630 | ||
| 0.125 | 0.024 | 0.125 | Histidine decarboxylase inhibitor | 0.086 0.039 DBMET01630 | ||
| 0.118 | 0.018 | 0.118 | Beta tubulin antagonist | 0.055 0.043 DBMET01630 | ||
| 0.172 | 0.073 | 0.275 | 3C-like protease (Human coronavirus) inhibitor | 0.275 0.018 DBMET01630 | DBMET01630 | |
| 0.13 | 0.031 | 0.13 | Anabolic | 0.118 0.041 DBMET01630 | ||
| 0.128 | 0.03 | 0.128 | Electrolyte absorption antagonist | 0.111 0.045 DBMET01630 | ||
| 0.108 | 0.012 | 0.108 | Potassium channel (ATP-sensitive) blocker | |||
| 0.124 | 0.028 | 0.124 | Thioredoxin inhibitor | 0.116 0.034 DBMET01630 | ||
| 0.099 | 0.004 | 0.099 | Adenylate cyclase 1 inhibitor | 0.08 0.008 DBMET01630 | ||
| 0.129 | 0.036 | 0.129 | Ca(v)2.2 blocker | |||
| 0.097 | 0.004 | 0.097 | GABA uptake inhibitor | 0.079 0.005 DBMET01630 | ||
| 0.131 | 0.039 | 0.131 | Mediator release inhibitor | |||
| 0.179 | 0.088 | 0.195 | Non-steroidal antiinflammatory agent | 0.195 0.075 DBMET01630 | DBMET01630 | |
| 0.112 | 0.022 | 0.112 | Granulocyte macrophage colony stimulating factor agonist | 0.105 0.029 DBMET01630 | ||
| 0.203 | 0.114 | 0.221 | MAP kinase kinase 3 inhibitor | 0.221 0.073 DBMET01630 | DBMET01630 | |
| 0.114 | 0.026 | 0.114 | Bile acid receptor antagonist | |||
| 0.103 | 0.015 | 0.103 | Purinergic P2X1 antagonist | 0.095 0.018 DBMET01630 | ||
| 0.094 | 0.009 | 0.094 | MDM2 inhibitor | |||
| 0.12 | 0.035 | 0.12 | Alcohol dehydrogenase inhibitor | 0.12 0.035 DBMET01630 | ||
| 0.093 | 0.009 | 0.093 | Heme oxygenase stimulant | 0.092 0.009 DBMET01630 | ||
| 0.135 | 0.052 | 0.156 | Papain-like protease (SARS coronavirus) inhibitor | 0.156 0.029 DBMET01630 | DBMET01630 | |
| 0.097 | 0.015 | 0.097 | MAP kinase kinase 7 inhibitor | 0.073 0.071 DBMET01630 | ||
| 0.098 | 0.016 | 0.135 | Protease 3C (Human rhinovirus) inhibitor | 0.135 0.008 DBMET01630 | DBMET01630 | |
| 0.089 | 0.009 | 0.089 | Thromboxane synthase inhibitor | |||
| 0.089 | 0.009 | 0.09 | Glucose-6-phosphate translocase inhibitor | 0.09 0.008 DBMET01630 | DBMET01630 | |
| 0.086 | 0.006 | 0.086 | Retinoid X alpha receptor agonist | 0.041 0.019 DBMET01630 | ||
| 0.124 | 0.045 | 0.124 | AMP-activated protein kinase stimulant | |||
| 0.091 | 0.015 | 0.091 | Glutamate (mGluR6) antagonist | 0.069 0.042 DBMET01630 | ||
| 0.147 | 0.071 | 0.199 | Thiol protease inhibitor | 0.199 0.039 DBMET01630 | DBMET01630 | |
| 0.083 | 0.007 | 0.083 | Retinoid X receptor agonist | 0.05 0.018 DBMET01630 | ||
| 0.08 | 0.004 | 0.08 | Kainate receptor agonist | 0.067 0.005 DBMET01630 | ||
| 0.104 | 0.028 | 0.119 | Na+ K+ transporting ATPase inhibitor | 0.119 0.017 DBMET01630 | DBMET01630 | |
| 0.125 | 0.049 | 0.125 | Chelator | |||
| 0.104 | 0.03 | 0.104 | Myeloperoxidase inhibitor | |||
| 0.133 | 0.059 | 0.133 | DNA polymerase I inhibitor | |||
| 0.09 | 0.017 | 0.09 | Alpha tubulin antagonist | |||
| 0.255 | 0.183 | 0.353 | Transcription factor inhibitor | 0.353 0.129 DBMET01630 | DBMET01630 | |
| 0.09 | 0.018 | 0.09 | Ornithine carbamoyltransferase inhibitor | 0.083 0.021 DBMET01630 | ||
| 0.091 | 0.02 | 0.091 | 3-Oxoacyl-[acyl-carrier-protein] synthase inhibitor | 0.058 0.042 DBMET01630 | ||
| 0.084 | 0.013 | 0.084 | Sphingosine kinase 2 inhibitor | |||
| 0.076 | 0.006 | 0.076 | Farnesoid X receptor agonist | 0.063 0.009 DBMET01630 | ||
| 0.087 | 0.017 | 0.107 | Exportin-1 inhibitor | 0.107 0.006 DBMET01630 | DBMET01630 | |
| 0.078 | 0.009 | 0.078 | Leukotriene C antagonist | 0.06 0.028 DBMET01630 | ||
| 0.143 | 0.073 | 0.143 | Lipid peroxidase inhibitor | |||
| 0.132 | 0.063 | 0.132 | MAP kinase kinase inhibitor | |||
| 0.12 | 0.052 | 0.12 | MAO A inhibitor | |||
| 0.18 | 0.113 | 0.18 | Glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase inhibitor | |||
| 0.088 | 0.02 | 0.088 | Aryl hydrocarbon receptor antagonist | 0.075 0.031 DBMET01630 | ||
| 0.123 | 0.056 | 0.143 | Caspase 3 inhibitor | 0.143 0.033 DBMET01630 | DBMET01630 | |
| 0.087 | 0.021 | 0.164 | Xanthine dehydrogenase inhibitor | 0.164 0.006 DBMET01630 | DBMET01630 | |
| 0.078 | 0.012 | 0.078 | Alpha-mannosidase inhibitor | 0.067 0.019 DBMET01630 | ||
| 0.18 | 0.115 | 0.18 | ErbB-1 antagonist | |||
| 0.112 | 0.046 | 0.112 | Potassium channel (Ca-activated) activator | |||
| 0.075 | 0.009 | 0.075 | Pregnane X receptor antagonist | 0.07 0.014 DBMET01630 | ||
| 0.22 | 0.155 | 0.22 | Thioredoxin glutathione reductase inhibitor | |||
| 0.11 | 0.045 | 0.11 | Estrogen receptor beta antagonist | |||
| 0.157 | 0.092 | 0.158 | Tumour necrosis factor antagonist | 0.158 0.091 DBMET01630 | DBMET01630 | |
| 0.088 | 0.024 | 0.088 | Phospholipase D inhibitor | 0.072 0.049 DBMET01630 | ||
| 0.088 | 0.024 | 0.088 | S-adenosyl-L-methionine decarboxylase inhibitor | 0.088 0.025 DBMET01630 | ||
| 0.07 | 0.006 | 0.07 | Retinoic acid alpha receptor agonist | 0.037 0.032 DBMET01630 | ||
| 0.083 | 0.02 | 0.083 | Prostaglandin F2 alpha antagonist | |||
| 0.079 | 0.018 | 0.079 | Peroxisome proliferator-activated receptor alpha agonist | |||
| 0.124 | 0.064 | 0.124 | Anesthetic local | 0.099 0.084 DBMET01630 | ||
| 0.078 | 0.018 | 0.078 | Sphingosine kinase inhibitor | 0.055 0.049 DBMET01630 | ||
| 0.071 | 0.011 | 0.071 | Heparanase inhibitor | 0.067 0.014 DBMET01630 | ||
| 0.089 | 0.031 | 0.089 | Calcium channel L-type blocker | |||
| 0.062 | 0.005 | 0.062 | Plasmepsin I inhibitor | |||
| 0.069 | 0.012 | 0.069 | Mannosidase inhibitor | 0.055 0.02 DBMET01630 | ||
| 0.065 | 0.008 | 0.065 | Guanylate cyclase inhibitor | 0.04 0.033 DBMET01630 | ||
| 0.061 | 0.005 | 0.061 | Retinoid X receptor antagonist | 0.046 0.016 DBMET01630 | ||
| 0.123 | 0.067 | 0.123 | DNA repair enzyme inhibitor | |||
| 0.102 | 0.047 | 0.171 | ABCA1 expression enhancer | 0.171 0.013 DBMET01630 | DBMET01630 | |
| 0.086 | 0.031 | 0.086 | GABA B receptor agonist | |||
| 0.093 | 0.039 | 0.093 | Glycine receptor antagonist | 0.087 0.046 DBMET01630 | ||
| 0.062 | 0.008 | 0.062 | Prostaglandin agonist | |||
| 0.071 | 0.017 | 0.071 | Dihydroorotate oxidase inhibitor | 0.062 0.025 DBMET01630 | ||
| 0.078 | 0.026 | 0.136 | Argininosuccinate synthase inhibitor | 0.136 0.013 DBMET01630 | DBMET01630 | |
| 0.058 | 0.006 | 0.058 | Uridine phosphorylase inhibitor | |||
| 0.056 | 0.005 | 0.056 | LFA antagonist | 0.031 0.015 DBMET01630 | ||
| 0.098 | 0.047 | 0.098 | Antineoplastic antibiotic | |||
| 0.088 | 0.037 | 0.088 | Estrogen receptor alpha antagonist | |||
| 0.125 | 0.074 | 0.125 | Antibacterial (Helicobacter pylori) | |||
| 0.055 | 0.005 | 0.055 | Prostaglandin EP2 agonist | |||
| 0.062 | 0.011 | 0.062 | Kainate receptor 2 antagonist | 0.041 0.021 DBMET01630 | ||
| 0.178 | 0.128 | 0.178 | Tumour necrosis factor alpha release inhibitor | |||
| 0.167 | 0.117 | 0.167 | Histone acetyltransferase inhibitor | |||
| 0.244 | 0.195 | 0.244 | DNA directed DNA polymerase inhibitor | |||
| 0.138 | 0.09 | 0.138 | MAP kinase 3 inhibitor | |||
| 0.083 | 0.036 | 0.083 | Phosphodiesterase VI inhibitor | |||
| 0.052 | 0.005 | 0.052 | Retinoid X alpha receptor antagonist | 0.04 0.015 DBMET01630 | ||
| 0.054 | 0.008 | 0.054 | Leukotriene C4 antagonist | 0.039 0.026 DBMET01630 | ||
| 0.057 | 0.011 | 0.057 | Fumarate hydratase inhibitor | 0.041 0.018 DBMET01630 | ||
| 0.127 | 0.08 | 0.127 | Calcium channel blocker | |||
| 0.096 | 0.05 | 0.096 | Glutamate release inhibitor | 0.084 0.077 DBMET01630 | ||
| 0.064 | 0.019 | 0.064 | Lysophosphatidic acid 3 receptor antagonist | |||
| 0.051 | 0.006 | 0.051 | Sodium/glucose cotransporter 2 inhibitor | |||
| 0.09 | 0.045 | 0.09 | D-Ala-D-Ala ligase inhibitor | 0.082 0.061 DBMET01630 | ||
| 0.091 | 0.046 | 0.091 | mTOR complex 2 inhibitor | |||
| 0.072 | 0.027 | 0.077 | Transcription factor RelA inhibitor | 0.077 0.021 DBMET01630 | DBMET01630 | |
| 0.084 | 0.041 | 0.084 | Metalloproteinase-9 inhibitor | |||
| 0.055 | 0.013 | 0.055 | Membrane dipeptidase inhibitor | 0.041 0.024 DBMET01630 | ||
| 0.066 | 0.024 | 0.066 | 3(or 17)beta-hydroxysteroid dehydrogenase inhibitor | |||
| 0.053 | 0.012 | 0.053 | 3-Hydroxyanthranilate 3,4-dioxygenase inhibitor | 0.044 0.024 DBMET01630 | ||
| 0.054 | 0.013 | 0.054 | Nicotinic acid receptor agonist | |||
| 0.073 | 0.032 | 0.073 | Neuraminidase (influenza) inhibitor | |||
| 0.153 | 0.114 | 0.153 | Psychostimulant | |||
| 0.088 | 0.05 | 0.088 | Inducible nitric-oxide synthase inhibitor | |||
| 0.043 | 0.004 | 0.043 | Estrogen-related receptor gamma antagonist | |||
| 0.062 | 0.024 | 0.062 | Carbonic anhydrase XIV inhibitor | |||
| 0.048 | 0.009 | 0.048 | Integrin alpha1beta1 antagonist | 0.04 0.022 DBMET01630 | ||
| 0.07 | 0.032 | 0.07 | Nitric oxide donor | |||
| 0.084 | 0.047 | 0.084 | Macrophage migration inhibitory factor inhibitor | |||
| 0.053 | 0.015 | 0.053 | Histone deacetylase 5 inhibitor | 0.053 0.015 DBMET01630 | ||
| 0.079 | 0.043 | 0.079 | Vanilloid 4 agonist | 0.071 0.06 DBMET01630 | ||
| 0.048 | 0.013 | 0.048 | Glutamate (mGluR8) agonist | 0.041 0.021 DBMET01630 | ||
| 0.041 | 0.007 | 0.041 | Sodium/glucose cotransporter inhibitor | |||
| 0.04 | 0.005 | 0.04 | Nicotinic acid receptor 2 antagonist | 0.033 0.009 DBMET01630 | ||
| 0.069 | 0.034 | 0.069 | Neuraminidase inhibitor | |||
| 0.041 | 0.007 | 0.041 | Prostaglandin E2 agonist | |||
| 0.041 | 0.007 | 0.041 | Retinoic acid receptor agonist | 0.023 0.017 DBMET01630 | ||
| 0.067 | 0.033 | 0.067 | Dopamine uptake inhibitor | |||
| 0.058 | 0.025 | 0.058 | Potassium channel (Inward rectifier) blocker | |||
| 0.037 | 0.005 | 0.037 | ICAM 1 antagonist | 0.024 0.013 DBMET01630 | ||
| 0.082 | 0.049 | 0.082 | Interferon agonist | |||
| 0.041 | 0.009 | 0.041 | Methionyl aminopeptidase 2 inhibitor | |||
| 0.044 | 0.012 | 0.044 | Prostaglandin EP3 antagonist | |||
| 0.035 | 0.004 | 0.035 | Retinoid X beta receptor antagonist | 0.026 0.006 DBMET01630 | ||
| 0.099 | 0.068 | 0.099 | Nav1.1 sodium channel blocker | |||
| 0.1 | 0.07 | 0.156 | Falcipain 3 inhibitor | 0.156 0.034 DBMET01630 | DBMET01630 | |
| 0.037 | 0.007 | 0.037 | Lysophosphatidic acid receptor 1 agonist | |||
| 0.057 | 0.027 | 0.057 | Phosphorylase inhibitor | 0.047 0.032 DBMET01630 | ||
| 0.048 | 0.018 | 0.048 | Estrogen receptor alpha agonist | |||
| 0.035 | 0.005 | 0.035 | Retinoic acid gamma receptor agonist | 0.022 0.017 DBMET01630 | ||
| 0.042 | 0.013 | 0.042 | HMG CoA reductase inhibitor | |||
| 0.048 | 0.019 | 0.048 | Sphingosine kinase 1 inhibitor | |||
| 0.044 | 0.015 | 0.044 | Vanilloid 3 antagonist | |||
| 0.06 | 0.031 | 0.06 | Glucosylceramidase inhibitor | |||
| 0.054 | 0.025 | 0.054 | Potassium channel Kv1.3 blocker | 0.048 0.032 DBMET01630 | ||
| 0.067 | 0.039 | 0.067 | Interferon inducer | |||
| 0.048 | 0.02 | 0.048 | Thymidine kinase inhibitor | |||
| 0.04 | 0.011 | 0.04 | Estrogen-related receptor beta antagonist | |||
| 0.05 | 0.022 | 0.05 | Geranyltranstransferase inhibitor | 0.05 0.023 DBMET01630 | ||
| 0.051 | 0.023 | 0.051 | Dihydroorotase inhibitor | |||
| 0.045 | 0.018 | 0.045 | Diamine oxidase inhibitor | |||
| 0.117 | 0.09 | 0.117 | Alkaline phosphatase inhibitor | |||
| 0.047 | 0.019 | 0.074 | Histone deacetylase 7 inhibitor | 0.074 0.012 DBMET01630 | DBMET01630 | |
| 0.034 | 0.007 | 0.034 | Prostaglandin F2 alpha agonist | |||
| 0.073 | 0.046 | 0.073 | Secretase beta inhibitor | |||
| 0.062 | 0.035 | 0.062 | Botulinum neurotoxin type A inhibitor | 0.059 0.039 DBMET01630 | ||
| 0.046 | 0.019 | 0.046 | Factor XIIIa inhibitor | |||
| 0.038 | 0.011 | 0.038 | NMDA 2D receptor antagonist | |||
| 0.107 | 0.081 | 0.107 | Beta amyloid protein antagonist | |||
| 0.053 | 0.027 | 0.053 | Adenosine deaminase inhibitor | |||
| 0.095 | 0.07 | 0.095 | Bronchodilator | |||
| 0.134 | 0.108 | 0.134 | CF transmembrane conductance regulator agonist | 0.13 0.118 DBMET01630 | ||
| 0.107 | 0.082 | 0.107 | Calcium channel N-type blocker | |||
| 0.048 | 0.023 | 0.048 | Kainate receptor antagonist | |||
| 0.045 | 0.02 | 0.06 | Histone deacetylase 9 inhibitor | 0.06 0.012 DBMET01630 | DBMET01630 | |
| 0.084 | 0.059 | 0.312 | 3C-Like protease (SARS coronavirus) inhibitor | 0.312 0.003 DBMET01630 | DBMET01630 | |
| 0.096 | 0.071 | 0.096 | Urease inhibitor | |||
| 0.033 | 0.009 | 0.033 | Retinoid X gamma receptor antagonist | |||
| 0.066 | 0.042 | 0.066 | Beta 3 adrenoreceptor antagonist | |||
| 0.095 | 0.072 | 0.095 | Gastric antisecretory | |||
| 0.084 | 0.061 | 0.084 | Transcription factor NF kappa B stimulant | |||
| 0.038 | 0.015 | 0.038 | ATP citrate lysase inhibitor | |||
| 0.037 | 0.014 | 0.037 | Leukotriene B4 receptor 1 antagonist | |||
| 0.045 | 0.022 | 0.045 | Dopamine D5 agonist | 0.039 0.029 DBMET01630 | ||
| 0.072 | 0.049 | 0.072 | Peroxisome proliferator-activated receptor gamma antagonist | |||
| 0.083 | 0.061 | 0.083 | Vanilloid agonist | |||
| 0.028 | 0.006 | 0.028 | Retinoic acid beta receptor agonist | |||
| 0.09 | 0.068 | 0.09 | Potassium channel (Voltage-sensitive) activator | |||
| 0.068 | 0.047 | 0.074 | Glutamate (mGluR7) antagonist | 0.074 0.036 DBMET01630 | DBMET01630 | |
| 0.039 | 0.018 | 0.039 | Peroxisome proliferator-activated receptor delta agonist | |||
| 0.055 | 0.034 | 0.055 | Nicotinic alpha3beta2 receptor antagonist | |||
| 0.027 | 0.006 | 0.027 | Prostacyclin agonist | |||
| 0.075 | 0.055 | 0.093 | Nicotinic alpha4beta2 receptor antagonist | 0.093 0.038 DBMET01630 | DBMET01630 | |
| 0.103 | 0.084 | 0.15 | Proteasome inhibitor | 0.15 0.047 DBMET01630 | DBMET01630 | |
| 0.045 | 0.026 | 0.045 | Dihydrofolate reductase inhibitor | |||
| 0.092 | 0.073 | 0.141 | Nitric-oxide synthase inhibitor | 0.141 0.026 DBMET01630 | DBMET01630 | |
| 0.029 | 0.009 | 0.029 | Leukotriene B4 receptor 2 antagonist | |||
| 0.038 | 0.019 | 0.038 | Ceramide glucosyltransferase inhibitor | |||
| 0.062 | 0.043 | 0.062 | Beta 2 adrenoreceptor agonist | |||
| 0.055 | 0.037 | 0.055 | Epithelial sodium channel blocker | |||
| 0.04 | 0.021 | 0.04 | 2,3-Oxidosqualene-lanosterol cyclase inhibitor | |||
| 0.023 | 0.005 | 0.023 | Integrin beta2 antagonist | 0.011 0.01 DBMET01630 | ||
| 0.063 | 0.045 | 0.063 | Calcium channel P-type blocker | |||
| 0.025 | 0.007 | 0.025 | Neuraminidase (Influenza B) inhibitor | |||
| 0.054 | 0.037 | 0.054 | Thromboxane antagonist | |||
| 0.026 | 0.009 | 0.026 | Retinoic acid alpha receptor antagonist | |||
| 0.102 | 0.084 | 0.102 | Topoisomerase II inhibitor | |||
| 0.03 | 0.013 | 0.03 | Prostaglandin H2 antagonist | |||
| 0.043 | 0.026 | 0.043 | Plasmepsin II inhibitor | |||
| 0.036 | 0.019 | 0.036 | Histone deacetylase class IIa inhibitor | 0.036 0.019 DBMET01630 | ||
| 0.022 | 0.005 | 0.022 | Thromboxane A2 agonist | 0.016 0.01 DBMET01630 | ||
| 0.049 | 0.032 | 0.049 | Dopamine beta hydroxylase inhibitor | 0.049 0.033 DBMET01630 | ||
| 0.029 | 0.012 | 0.029 | Thymidine kinase (Herpes simplex virus 1) inhibitor | |||
| 0.034 | 0.017 | 0.034 | Glutamate (mGluR3) agonist | |||
| 0.052 | 0.035 | 0.052 | Thromboxane A2 antagonist | |||
| 0.022 | 0.005 | 0.022 | Lysophosphatidic acid receptor 3 agonist | |||
| 0.051 | 0.034 | 0.051 | CD45 antagonist | |||
| 0.055 | 0.039 | 0.055 | Immunoglobulin Fc receptor antagonist | |||
| 0.024 | 0.008 | 0.024 | Retinoic acid receptor antagonist | |||
| 0.037 | 0.022 | 0.037 | Phosphoglycerate kinase inhibitor | |||
| 0.074 | 0.059 | 0.074 | Sphingosine 1-phosphate receptor antagonist | |||
| 0.038 | 0.023 | 0.038 | Progesterone antagonist | |||
| 0.05 | 0.036 | 0.062 | Prolyl endopeptidase inhibitor | 0.062 0.022 DBMET01630 | DBMET01630 | |
| 0.031 | 0.017 | 0.031 | Hypoxanthine phosphoribosyltransferase inhibitor | 0.03 0.018 DBMET01630 | ||
| 0.025 | 0.011 | 0.025 | Isoleucine-tRNA ligase inhibitor | |||
| 0.032 | 0.019 | 0.032 | Lysophosphatidic acid 2 receptor antagonist | |||
| 0.046 | 0.033 | 0.046 | Glycine transporter 2 inhibitor | |||
| 0.116 | 0.103 | 0.116 | Nav1.6 sodium channel blocker | |||
| 0.033 | 0.02 | 0.033 | Methionyl aminopeptidase 1 inhibitor | |||
| 0.028 | 0.015 | 0.028 | Thymidine phosphorylase inhibitor | |||
| 0.061 | 0.049 | 0.1 | CDC25B inhibitor | 0.1 0.016 DBMET01630 | DBMET01630 | |
| 0.048 | 0.037 | 0.048 | Estrogen agonist | |||
| 0.044 | 0.033 | 0.044 | Fructose-1,6-bisphosphatase inhibitor | |||
| 0.017 | 0.006 | 0.017 | Integrin alphaLbeta2 antagonist | |||
| 0.042 | 0.032 | 0.042 | Heme oxygenase inhibitor | |||
| 0.034 | 0.024 | 0.034 | Calcium-independent phospholipase A2 inhibitor | |||
| 0.082 | 0.072 | 0.082 | ATPase (Vacuolar H+) inhibitor | |||
| 0.024 | 0.015 | 0.024 | Retinoid X gamma receptor agonist | |||
| 0.199 | 0.189 | 0.199 | Sodium/bile acid cotransporter inhibitor | |||
| 0.014 | 0.005 | 0.014 | Thromboxane agonist | |||
| 0.018 | 0.009 | 0.018 | Vitamin D receptor agonist | |||
| 0.027 | 0.018 | 0.027 | Lysine carboxypeptidase inhibitor | |||
| 0.165 | 0.156 | 0.266 | Calpain inhibitor | 0.266 0.051 DBMET01630 | DBMET01630 | |
| 0.1 | 0.092 | 0.1 | M18 aspartyl aminopeptidase inhibitor | |||
| 0.02 | 0.011 | 0.02 | Antibiotic Anthracycline-like | |||
| 0.07 | 0.062 | 0.073 | Topoisomerase II alpha inhibitor | 0.073 0.058 DBMET01630 | DBMET01630 | |
| 0.012 | 0.004 | 0.012 | Mannitol 2-dehydrogenase inhibitor | |||
| 0.047 | 0.039 | 0.047 | Bombesin 2 receptor antagonist | |||
| 0.032 | 0.024 | 0.032 | Sirtuin 2 inhibitor | |||
| 0.022 | 0.015 | 0.022 | Glutamate (mGluR1a) agonist | |||
| 0.022 | 0.014 | 0.022 | Retinoid X beta receptor agonist | |||
| 0.122 | 0.115 | 0.122 | Cyclin-dependent kinase 8 inhibitor | |||
| 0.036 | 0.029 | 0.036 | TRPM8 blocker | |||
| 0.031 | 0.024 | 0.031 | Estradiol 17 beta-dehydrogenase 3 inhibitor | |||
| 0.03 | 0.023 | 0.03 | Prostaglandin D2 agonist | |||
| 0.051 | 0.045 | 0.051 | Beta 1 adrenoreceptor antagonist | |||
| 0.018 | 0.012 | 0.02 | Methylmalonyl-CoA mutase inhibitor | 0.02 0.01 DBMET01630 | DBMET01630 | |
| 0.021 | 0.015 | 0.021 | Kainate receptor 1 antagonist | |||
| 0.025 | 0.019 | 0.025 | Prostaglandin EP4 antagonist | |||
| 0.019 | 0.013 | 0.019 | Estrogen-related receptor gamma agonist | |||
| 0.024 | 0.019 | 0.024 | Glutamate (mGluR1) agonist | |||
| 0.102 | 0.098 | 0.102 | Cyclooxygenase 1 inhibitor | |||
| 0.108 | 0.104 | 0.108 | Interleukin 4 antagonist | |||
| 0.056 | 0.051 | 0.056 | NMDA 2C receptor antagonist | |||
| 0.034 | 0.03 | 0.034 | 5-Alpha-reductase inhibitor | |||
| 0.049 | 0.045 | 0.049 | Maillard reaction inhibitor | |||
| 0.026 | 0.023 | 0.026 | Bradykinin B2 receptor agonist | |||
| 0.046 | 0.042 | 0.046 | Cytokine production stimulant | |||
| 0.038 | 0.035 | 0.038 | Sphingosine 1-phosphate receptor 1 agonist | |||
| 0.02 | 0.017 | 0.02 | Thymidine kinase (Herpes simplex virus 2) inhibitor | |||
| 0.112 | 0.109 | 0.527 | Neurotrophic factor | 0.527 0.003 DBMET01630 | DBMET01630 | |
| 0.089 | 0.087 | 0.089 | Glutamate (mGluR7) agonist | |||
| 0.011 | 0.009 | 0.011 | Retinoic acid receptor gamma antagonist | |||
| 0.041 | 0.039 | 0.041 | Carbonic anhydrase VII inhibitor | |||
| 0.036 | 0.034 | 0.036 | Histone deacetylase 8 inhibitor | |||
| 0.021 | 0.019 | 0.021 | CYP24 inhibitor | 0.02 0.019 DBMET01630 | ||
| 0.032 | 0.03 | 0.032 | Arginase inhibitor | |||
| 0.027 | 0.026 | 0.037 | Histone deacetylase 11 inhibitor | 0.037 0.019 DBMET01630 | DBMET01630 | |
| 0.027 | 0.026 | 0.037 | Histone deacetylase class IV inhibitor | 0.037 0.019 DBMET01630 | DBMET01630 | |
| 0.024 | 0.023 | 0.027 | Complement factor 1s inhibitor | 0.027 0.012 DBMET01630 | DBMET01630 | |
| 0.013 | 0.012 | 0.013 | Prostaglandin EP4 agonist | |||
| 0.017 | 0.016 | 0.017 | Inosine monophosphate dehydrogenase 2 inhibitor | |||
| 0.011 | 0.01 | 0.011 | Retinoic acid beta receptor antagonist | |||
| 0.016 | 0.015 | 0.016 | Telomerase stimulant | |||
| 0.023 | 0.03 | 0.027 | Thrombin receptor antagonist | 0.027 0.022 DBMET01630 | DBMET01630 | |
| 0.176 | 0.183 | 0.206 | Hypoxia-inducible factor 1 alpha inhibitor | 0.206 0.145 DBMET01630 | DBMET01630 | |
| 0.019 | 0.03 | 0.032 | Histone deacetylase 10 inhibitor | 0.032 0.019 DBMET01630 | DBMET01630 | |
| 0.061 | 0.073 | 0.097 | CYP2A6 inhibitor | 0.097 0.037 DBMET01630 | DBMET01630 | |
| 0.041 | 0.055 | 0.048 | H+/K+-transporting ATPase inhibitor | 0.048 0.04 DBMET01630 | DBMET01630 | |
| 0.062 | 0.081 | 0.081 | Metalloproteinase-2 inhibitor | 0.081 0.052 DBMET01630 | DBMET01630 | |
| 0.006 | 0.029 | 0.011 | Immunosuppressant Cyclosporine-like | 0.011 0.009 DBMET01630 | DBMET01630 | |
| 0.046 | 0.07 | 0.09 | Cyclin D1 inhibitor | 0.09 0.011 DBMET01630 | DBMET01630 | |
| 0.03 | 0.054 | 0.037 | Potassium channel Kv1.1 blocker | 0.037 0.029 DBMET01630 | DBMET01630 | |
| 0.038 | 0.063 | 0.091 | Aromatase inhibitor | 0.091 0.023 DBMET01630 | DBMET01630 | |
| 0.033 | 0.061 | 0.047 | AICAR transformylase inhibitor | 0.047 0.026 DBMET01630 | DBMET01630 | |
| 0.034 | 0.063 | 0.144 | Aldose reductase inhibitor | 0.144 0.011 DBMET01630 | DBMET01630 | |
| 0.053 | 0.083 | 0.085 | Cathepsin G inhibitor | 0.085 0.04 DBMET01630 | DBMET01630 | |
| 0.05 | 0.084 | 0.117 | Elastase 1 inhibitor | 0.117 0.013 DBMET01630 | DBMET01630 | |
| 0.041 | 0.077 | 0.336 | TRPA1 antagonist | 0.336 0.004 DBMET01630 | DBMET01630 | |
| 0.006 | 0.047 | 0.038 | 3C-Like protease (MERS coronavirus) inhibitor | 0.038 0.002 DBMET01630 | DBMET01630 | |
| 0.029 | 0.082 | 0.081 | Protein 50S ribosomal subunit inhibitor | 0.081 0.019 DBMET01630 | DBMET01630 | |
| 0.105 | 0.161 | 0.125 | Heat shock protein 90 alpha antagonist | 0.125 0.118 DBMET01630 | DBMET01630 | |
| 0.015 | 0.077 | 0.034 | Trypsin II inhibitor | 0.034 0.017 DBMET01630 | DBMET01630 | |
| 0.066 | 0.137 | 0.096 | Interleukin 1 beta converting enzyme inhibitor | 0.096 0.063 DBMET01630 | DBMET01630 | |
| 0.028 | 0.106 | 0.048 | Farnesyltransferase inhibitor | 0.048 0.03 DBMET01630 | DBMET01630 | |
| 0.043 | 0.123 | 0.111 | Caspase 9 inhibitor | 0.111 0.011 DBMET01630 | DBMET01630 | |
| 0.027 | 0.119 | 0.057 | Human rhinovirus A protease inhibitor | 0.057 0.037 DBMET01630 | DBMET01630 | |
| 0.022 | 0.124 | 0.051 | Cathepsin L inhibitor | 0.051 0.049 DBMET01630 | DBMET01630 | |
| 0.034 | 0.136 | 0.066 | Amidase inhibitor | 0.066 0.056 DBMET01630 | DBMET01630 | |
| 0.141 | 0.251 | 0.322 | Calpain 2 inhibitor | 0.322 0.101 DBMET01630 | DBMET01630 | |
| 0.049 | 0.166 | 0.125 | Falcipain 2 inhibitor | 0.125 0.04 DBMET01630 | DBMET01630 | |
| 0.05 | 0.17 | 0.154 | Falcipain inhibitor | 0.154 0.029 DBMET01630 | DBMET01630 | |
| 0.019 | 0.143 | 0.073 | Plasminogen activator inhibitor | 0.073 0.03 DBMET01630 | DBMET01630 | |
| 0.059 | 0.19 | 0.361 | Bone formation stimulant | 0.361 0.012 DBMET01630 | DBMET01630 | |
| 0.132 | 0.267 | 0.501 | Angiogenesis inhibitor | 0.501 0.029 DBMET01630 | DBMET01630 | |
| 0.037 | 0.214 | 0.089 | Protease inhibitor | 0.089 0.076 DBMET01630 | DBMET01630 | |
| 0.005 | 0.246 | 0.17 | Calpain 1 inhibitor | 0.17 0.003 DBMET01630 | DBMET01630 | |
| 0.018 | 0.274 | 0.086 | Lipase inhibitor | 0.086 0.037 DBMET01630 | DBMET01630 | |
| 0.012 | 0.297 | 0.492 | CDK4/cyclin D1 inhibitor | 0.492 0.003 DBMET01630 | DBMET01630 | |
| 0.028 | 0.344 | 0.08 | Chymotrypsin inhibitor | 0.08 0.055 DBMET01630 | DBMET01630 | |
| 0.016 | 0.396 | 0.139 | Cathepsin B inhibitor | 0.139 0.008 DBMET01630 | DBMET01630 | |
| 0.026 | 0.406 | 0.095 | Factor XII inhibitor | 0.095 0.043 DBMET01630 | DBMET01630 | |
| 0.009 | 0.414 | 0.05 | Plasmin inhibitor | 0.05 0.032 DBMET01630 | DBMET01630 | |
| 0.021 | 0.432 | 0.06 | Trypsin inhibitor | 0.06 0.048 DBMET01630 | DBMET01630 | |
| 0.008 | 0.461 | 0.308 | CDK4/cyclin D inhibitor | 0.308 0.004 DBMET01630 | DBMET01630 | |
| 0.047 | 0.523 | 0.277 | Factor V inhibitor | 0.277 0.002 DBMET01630 | DBMET01630 | |
| 0.008 | 0.603 | 0.199 | CDK/cyclin complex inhibitor | 0.199 0.019 DBMET01630 | DBMET01630 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |